Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $4.4 billion as of September 30, 2025, supporting cash runway into profitability
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- ROIV Upcoming Earnings Report: What to Expect?
- Vor Bio appoints Sokolove as Chief Medical Officer
- Roivant Sciences price target raised to $25 from $16 at Citi
- Roivant Sciences files automatic mixed securities shelf
- Hold Rating for Roivant Sciences Amid Promising Developments and Competitive Challenges